IRC Section 174 amortization of R&D expenditures.
Source-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- Not reported
- Expenses
- $500,000.00
- Registrant
- EXELIXIS INC.
- Client
- EXELIXIS INC.
- Filing UUID
- 7fa1e0fa-1158-467f-aecb-83c3347b01ac
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Proposals related to drug pricing including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.